Terpenoids: natural products for cancer therapy

Bibliography

• Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-37
   PubMed Web of Science ®Google Scholar
• Gershenzon J, Dudareva N. The function of terpene natural products in the natural world. Nat Chem Biol 2007;3:408-14
   PubMed Web of Science ®Google Scholar
• Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. Invest New Drugs 2012. [Epub ahead of print]
   Web of Science ®Google Scholar
• Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009;20:880-92
   PubMed Web of Science ®Google Scholar
• Sun J. D-Limonene: safety and clinical applications. Altern Med Rev 2007;12:259-64
   PubMed Web of Science ®Google Scholar
• Rabi T, Bishayee A. D-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: generation of reactive oxygen species and induction of apoptosis. J Carcinog 2009;8:9
   PubMedGoogle Scholar
• Vigushin DM, Poon GK, Boddy A, Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol 1998;42:111-17
   PubMed Web of Science ®Google Scholar
• Clegg RJ, Middleton B, Bell GD, The mechanism of cyclic monoterpene inhibition of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase in vivo in the rat. J Biol Chem 1982;257:2294-9
   PubMed Web of Science ®Google Scholar
• Kawata S, Nagase T, Yamasaki E, Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 1994;69:1015-20
   PubMed Web of Science ®Google Scholar
• Kaji I, Tatsuta M, Iishi H, Inhibition by d-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not involve p21(ras) plasma membrane association. Int J Cancer 2001;93:441-4
   PubMed Web of Science ®Google Scholar
• Ji J, Zhang L, Wu YY, Induction of apoptosis by d-limonene is mediated by a caspase-dependent mitochondrial death pathway in human leukemia cells. Leuk Lymphoma 2006;47:2617-24
   PubMed Web of Science ®Google Scholar
• Liu D, Chen Z. The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem 2009;9:392-6
   PubMed Web of Science ®Google Scholar
• McCluskey A, Bowyer MC, Collins E, Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg Med Chem Lett 2000;10:1687-90
   PubMed Web of Science ®Google Scholar
• Hennings H, Boutwell RK. Studies on the mechanism of skin tumor promotion. Cancer Res 1970;30:312-20
   PubMed Web of Science ®Google Scholar
• Chen YN, Chen JC, Yin SC, Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002;100:158-65
   PubMed Web of Science ®Google Scholar
• Huan SK, Lee HH, Liu DZ, Cantharidin-induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line. Toxicology 2006;223:136-43
   PubMed Web of Science ®Google Scholar
• Huh JE, Kang KS, Chae C, Roles of p38 and JNK mitogen-activated protein kinase pathways during cantharidin-induced apoptosis in U937 cells. Biochem Pharmacol 2004;67:1811-18
   PubMed Web of Science ®Google Scholar
• Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 1993;330:283-6
   PubMed Web of Science ®Google Scholar
• Sakoff JA, Ackland SP, Baldwin ML, Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues. Invest New Drugs 2002;20:1-11
   PubMed Web of Science ®Google Scholar
• McCluskey A, Ackland SP, Bowyer MC, Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg Chem 2003;31:68-79
   PubMed Web of Science ®Google Scholar
• Bertini I, Calderone V, Fragai M, Structural basis of serine/threonine phosphatase inhibition by the archetypal small molecules cantharidin and norcantharidin. J Med Chem 2009;52:4838-43
   PubMed Web of Science ®Google Scholar
• Kalev P, Sablina AA. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem 2011;11:38-46
   PubMedGoogle Scholar
• Li W, Chen Z, Zong Y, PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKalpha and sustained activation of the NF-kappaB pathway. Cancer Lett 2011;304:117-27
   Google Scholar
• Li W, Xie L, Chen Z, Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci 2010;101:1226-33
   PubMed Web of Science ®Google Scholar
• Meshnick SR. Artemisinin antimalarials: mechanisms of action and resistance. Med Trop (Mars) 1998;58:13-17
   PubMedGoogle Scholar
• Burrows JN, Chibale K, Wells TN. The state of the art in anti-malarial drug discovery and development. Curr Top Med Chem 2011;11:1226-54
   PubMed Web of Science ®Google Scholar
• Liu R, Dong HF, Jiang MS. Artemisinin: the gifts from traditional Chinese medicine not only for malaria control but also for schistosomiasis control. Parasitol Res 2011;110(5):2071-4
   PubMed Web of Science ®Google Scholar
• Yang ZS, Zhou WL, Sui Y, Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters. J Med Chem 2005;48:4608-17
   PubMed Web of Science ®Google Scholar
• Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 2009;11:e32
   PubMed Web of Science ®Google Scholar
• Tan W, Lu J, Huang M, Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med 2011;6:27
   PubMed Web of Science ®Google Scholar
• Chaturvedi D, Goswami A, Saikia PP, Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chem Soc Rev 2010;39:435-54
   PubMed Web of Science ®Google Scholar
• Jiao Y, Ge CM, Meng QH, Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 2007;28:1045-56
   PubMed Web of Science ®Google Scholar
• Hou J, Wang D, Zhang R, Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008;14:5519-30
   PubMed Web of Science ®Google Scholar
• Lu JJ, Meng LH, Cai YJ, Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther 2008;7:1017-23
   PubMed Web of Science ®Google Scholar
• Chen H, Sun B, Pan S, Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009;20:131-40
   PubMed Web of Science ®Google Scholar
• He Q, Shi J, Shen XL, Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol Ther 2010;9:819-24
   PubMed Web of Science ®Google Scholar
• Lu JJ, Chen SM, Zhang XW, The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest New Drugs 2011;29:1276-83
   PubMed Web of Science ®Google Scholar
• Lu JJ, Meng LH, Shankavaram UT, Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010;80:22-30
   PubMed Web of Science ®Google Scholar
• Wang SJ, Gao Y, Chen H, Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 2010;293:99-108
   PubMed Web of Science ®Google Scholar
• Li S, Xue F, Cheng Z, Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int J Hematol 2009;90:513-21
   PubMed Web of Science ®Google Scholar
• Efferth T, Dunstan H, Sauerbrey A, The anti-malarial artesunate is also active against cancer. Int J Oncol 2001;18:767-73
   PubMed Web of Science ®Google Scholar
• Efferth T, Sauerbrey A, Olbrich A, Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003;64:382-94
   PubMed Web of Science ®Google Scholar
• Michaelis M, Kleinschmidt MC, Barth S, Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol 2010;79:130-6
   PubMed Web of Science ®Google Scholar
• Reungpatthanaphong P, Mankhetkorn S. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 2002;25:1555-61
   PubMed Web of Science ®Google Scholar
• Lu JJ, Chen SM, Ding J, Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line. Mol Cell Biochem 2012;360:329-37
   PubMed Web of Science ®Google Scholar
• Du JH, Zhang HD, Ma ZJ, Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 2010;65:895-902
   PubMed Web of Science ®Google Scholar
• Chen T, Li M, Zhang R, Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2009;13:1358-70
   PubMed Web of Science ®Google Scholar
• Zhang S, Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PLoS One 2009;4:e7472
   PubMed Web of Science ®Google Scholar
• Efferth T, Benakis A, Romero MR, Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 2004;37:998-1009
   PubMed Web of Science ®Google Scholar
• Sertel S, Eichhorn T, Sieber S, Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem Biol Interact 2010;185:42-52
   PubMed Web of Science ®Google Scholar
• Willoughby JA Sr, Sundar SN, Cheung M, Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009;284:2203-13
   PubMed Web of Science ®Google Scholar
• Chen H, Sun B, Wang S, Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol 2010;136:897-903
   PubMed Web of Science ®Google Scholar
• Mu D, Zhang W, Chu D, The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. Cancer Chemother Pharmacol 2008;61:639-45
   PubMed Web of Science ®Google Scholar
• Handrick R, Ontikatze T, Bauer KD, Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther 2010;9:2497-510
   PubMed Web of Science ®Google Scholar
• Rasheed SA, Efferth T, Asangani IA, First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 2010;127:1475-85
   PubMed Web of Science ®Google Scholar
• Hwang YP, Yun HJ, Kim HG, Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. Biochem Pharmacol 2010;79:1714-26
   PubMed Web of Science ®Google Scholar
• Chen HH, Zhou HJ, Wang WQ, Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 2004;53:423-32
   PubMed Web of Science ®Google Scholar
• Buommino E, Baroni A, Canozo N, Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs 2009;27:412-18
   PubMed Web of Science ®Google Scholar
• Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005;45:1345-59
   PubMed Web of Science ®Google Scholar
• Sung HJ, Choi SM, Yoon Y, Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3. Exp Mol Med 1999;31:174-8
   PubMed Web of Science ®Google Scholar
• Liu JJ, Lin DJ, Liu PQ, Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro. J Biomed Sci 2006;13:813-23
   PubMed Web of Science ®Google Scholar
• Wang X, Wei Y, Yuan S, Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 2005;116:799-807
   PubMed Web of Science ®Google Scholar
• Su CC, Lin YH. Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med 2008;22:357-61
   PubMed Web of Science ®Google Scholar
• Su CC, Chen GW, Kang JC, Growth inhibition and apoptosis induction by tanshinone IIA in human colon adenocarcinoma cells. Planta Med 2008;74:1357-62
   PubMed Web of Science ®Google Scholar
• Wu WL, Chang WL, Chen CF. Cytotoxic activities of tanshinones against human carcinoma cell lines. Am J Chin Med 1991;19:207-16
   PubMed Web of Science ®Google Scholar
• Tang Z, Tang Y, Fu L. Growth inhibition and apoptosis induction in human hepatoma cells by tanshinone II A. J Huazhong Univ Sci Technolog Med Sci 2003;23:166-8; 172
   PubMedGoogle Scholar
• Yuan SL, Wei YQ, Wang XJ, Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol 2004;10:2024-8
   PubMed Web of Science ®Google Scholar
• Lee WY, Cheung CC, Liu KW, Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. J Nat Prod 2010;73:854-9
   PubMed Web of Science ®Google Scholar
• Jiao JW, Wen F. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol Rep 2011;25:781-8
   PubMed Web of Science ®Google Scholar
• Su CC, Lin YH. Tanshinone IIA down-regulates the protein expression of ErbB-2 and up-regulates TNF-alpha in colon cancer cells in vitro and in vivo. Int J Mol Med 2008;22:847-51
   PubMed Web of Science ®Google Scholar
• Dai ZK, Qin JK, Huang JE, Tanshinone IIA activates calcium-dependent apoptosis signaling pathway in human hepatoma cells. J Nat Med 2011;66(1):192-201
   PubMed Web of Science ®Google Scholar
• Won SH, Lee HJ, Jeong SJ, Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway. Biol Pharm Bull 2010;33:1828-34
   PubMed Web of Science ®Google Scholar
• Chiu TL, Su CC. Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med 2010;25:231-6
   PubMed Web of Science ®Google Scholar
• Cheng CY, Su CC. Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential. Mol Med Report 2010;3:645-50
   PubMed Web of Science ®Google Scholar
• Zhang K, Li J, Meng W, C/EBPbeta and CHOP participate in tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro. Int J Hematol 2010;92:571-8
   PubMed Web of Science ®Google Scholar
• Wang J, Wang X, Jiang S, Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J Neurooncol 2007;82:11-21
   PubMed Web of Science ®Google Scholar
• Yuxian X, Feng T, Ren L, Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo. Tumori 2009;95:789-95
   PubMed Web of Science ®Google Scholar
• Shan YF, Shen X, Xie YK, Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacol Sin 2009;30:1537-42
   PubMed Web of Science ®Google Scholar
• Tsai MY, Yang RC, Wu HT, Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells. Cancer Lett 2011;310:198-206
   PubMed Web of Science ®Google Scholar
• Lee CY, Sher HF, Chen HW, Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther 2008;7:3527-38
   PubMed Web of Science ®Google Scholar
• Su CC, Chen GW, Lin JG. Growth inhibition and apoptosis induction by tanshinone I in human colon cancer Colo 205 cells. Int J Mol Med 2008;22:613-18
   PubMed Web of Science ®Google Scholar
• Nizamutdinova IT, Lee GW, Son KH, Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol 2008;33:485-91
   PubMed Web of Science ®Google Scholar
• Nizamutdinova IT, Lee GW, Lee JS, Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis 2008;29:1885-92
   PubMed Web of Science ®Google Scholar
• Liu JJ, Liu WD, Yang HZ, Inactivation of PI3k/Akt signaling pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis in myeloid leukemia cells in vitro. Ann Hematol 2010;89:1089-97
   PubMed Web of Science ®Google Scholar
• Lee WY, Liu KW, Yeung JH. Reactive oxygen species-mediated kinase activation by dihydrotanshinone in tanshinones-induced apoptosis in HepG2 cells. Cancer Lett 2009;285:46-57
   PubMed Web of Science ®Google Scholar
• Park IJ, Kim MJ, Park OJ, Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett 2010;298:88-98
   PubMed Web of Science ®Google Scholar
• Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011;11:377-83
   PubMed Web of Science ®Google Scholar
• Qiu D, Zhao G, Aoki Y, Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999;274:13443-50
   PubMed Web of Science ®Google Scholar
• Westerheide SD, Kawahara TL, Orton K, Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006;281:9616-22
   PubMed Web of Science ®Google Scholar
• Chang WT, Kang JJ, Lee KY, Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001;276:2221-7
   PubMed Web of Science ®Google Scholar
• McCallum C, Kwon S, Leavitt P, Triptolide binds covalently to a 90 kDa nuclear protein. Role of epoxides in binding and activity. Immunobiology 2007;212:549-56
   PubMed Web of Science ®Google Scholar
• Vispe S, DeVries L, Creancier L, Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther 2009;8:2780-90
   PubMed Web of Science ®Google Scholar
• Wang Y, Lu JJ, He L, Triptolide (TPL) Inhibits Global Transcription by Inducing Proteasome-Dependent Degradation of RNA Polymerase II (Pol II). PLoS One 2011;6:e23993
   PubMedGoogle Scholar
• Leuenroth SJ, Okuhara D, Shotwell JD, Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007;104:4389-94
   PubMed Web of Science ®Google Scholar
• Titov DV, Gilman B, He QL, XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011;7:182-8
   PubMed Web of Science ®Google Scholar
• Zhou ZL, Luo ZG, Yu B, Increased accumulation of hypoxia-inducible factor-1alpha with reduced transcriptional activity mediates the antitumor effect of triptolide. Mol Cancer 2010;9:268
   PubMed Web of Science ®Google Scholar
• Chiu P, Leung LT, Ko BC. Pseudolaric acids: isolation, bioactivity and synthetic studies. Nat Prod Rep 2010;27:1066-83
   PubMed Web of Science ®Google Scholar
• Pan DJ, Li ZL, Hu CQ, The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and -B and related derivatives. Planta Med 1990;56:383-5
   PubMed Web of Science ®Google Scholar
• Wong VK, Chiu P, Chung SS, Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 2005;11:6002-11
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65
   PubMed Web of Science ®Google Scholar
• Anton Aparicio LM, Pulido EG, Gallego GA. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs 2011;23(1):1-11
   Web of Science ®Google Scholar
• Tan WF, Zhang XW, Li MH, Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. Eur J Pharmacol 2004;499:219-28
   PubMed Web of Science ®Google Scholar
• Li MH, Miao ZH, Tan WF, Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res 2004;10:8266-74
   PubMed Web of Science ®Google Scholar
• Yu JH, Wang HJ, Li XR, Protein tyrosine kinase, JNK, and ERK involvement in pseudolaric acid B-induced apoptosis of human breast cancer MCF-7 cells. Acta Pharmacol Sin 2008;29:1069-76
   Google Scholar
• Yu J, Li X, Tashiro S, Bcl-2 family proteins were involved in pseudolaric acid B-induced autophagy in murine fibrosarcoma L929 cells. J Pharmacol Sci 2008;107:295-302
   PubMed Web of Science ®Google Scholar
• Lim CW, Chan TK, Ng DS, Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer. Clin Exp Pharmacol Physiol 2011;39(3):300-10
   Web of Science ®Google Scholar
• Yu BC, Hung CR, Chen WC, Antihyperglycemic effect of andrographolide in streptozotocin-induced diabetic rats. Planta Med 2003;69:1075-9
   PubMed Web of Science ®Google Scholar
• Xia YF, Ye BQ, Li YD, Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 2004;173:4207-17
   PubMed Web of Science ®Google Scholar
• Wang YJ, Wang JT, Fan QX, Andrographolide inhibits NF-kappaBeta activation and attenuates neointimal hyperplasia in arterial restenosis. Cell Res 2007;17:933-41
   PubMed Web of Science ®Google Scholar
• Wang LJ, Zhou X, Wang W, Andrographolide inhibits oral squamous cell carcinogenesis through NF-kappaB inactivation. J Dent Res 2011;90:1246-52
   PubMed Web of Science ®Google Scholar
• Kuttan G, Pratheeshkumar P, Manu KA, Inhibition of tumor progression by naturally occurring terpenoids. Pharm Biol 2011;49:995-1007
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Yang Y, Bandobashi K, Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005;4:578-86
   PubMed Web of Science ®Google Scholar
• Jin H, Tan X, Liu X, Downregulation of AP-1 gene expression is an initial event in the oridonin-mediated inhibition of colorectal cancer: studies in vitro and in vivo. J Gastroenterol Hepatol 2011;26:706-15
   PubMed Web of Science ®Google Scholar
• Hu HZ, Yang YB, Xu XD, Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 2007;28:1819-26
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu Y, Wu D, NF-kappab facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway. Arch Biochem Biophys 2009;489:25-33
   PubMed Web of Science ®Google Scholar
• Cheng Y, Qiu F, Ikejima T. Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells. Autophagy 2009;5:430-1
   PubMed Web of Science ®Google Scholar
• Cheng Y, Qiu F, Ye YC, Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells. FEBS J 2009;276:1291-306
   PubMed Web of Science ®Google Scholar
• Zhang YH, Wu YL, Tashiro S, Reactive oxygen species contribute to oridonin-induced apoptosis and autophagy in human cervical carcinoma HeLa cells. Acta Pharmacol Sin 2011;32:1266-75
   PubMed Web of Science ®Google Scholar
• Calixto JB, Campos MM, Otuki MF, Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 2004;70:93-103
   PubMed Web of Science ®Google Scholar
• Allison AC, Cacabelos R, Lombardi VR, Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:1341-57
   PubMed Web of Science ®Google Scholar
• Li H, Zhang YY, Huang XY, Beneficial effect of tripterine on systemic lupus erythematosus induced by active chromatin in BALB/c mice. Eur J Pharmacol 2005;512:231-7
   PubMed Web of Science ®Google Scholar
• Zhang DH, Marconi A, Xu LM, Tripterine inhibits the expression of adhesion molecules in activated endothelial cells. J Leukoc Biol 2006;80:309-19
   PubMed Web of Science ®Google Scholar
• Pinna GF, Fiorucci M, Reimund JM, Celastrol inhibits pro-inflammatory cytokine secretion in Crohn's disease biopsies. Biochem Biophys Res Commun 2004;322:778-86
   PubMed Web of Science ®Google Scholar
• Yu X, Tao W, Jiang F, Celastrol attenuates hypertension-induced inflammation and oxidative stress in vascular smooth muscle cells via induction of heme oxygenase-1. Am J Hypertens 2010;23:895-903
   PubMed Web of Science ®Google Scholar
• Seo WY, Ju SM, Song HY, Celastrol suppresses IFN-gamma-induced ICAM-1 expression and subsequent monocyte adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells. Biochem Biophys Res Commun 2010;398:140-5
   PubMed Web of Science ®Google Scholar
• Pang X, Yi Z, Zhang J, Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 2010;70:1951-9
   PubMed Web of Science ®Google Scholar
• Yang H, Chen D, Cui QC, Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006;66:4758-65
   PubMed Web of Science ®Google Scholar
• Sethi G, Ahn KS, Pandey MK, Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007;109:2727-35
   PubMed Web of Science ®Google Scholar
• Salminen A, Lehtonen M, Paimela T, Celastrol: molecular targets of Thunder God Vine. Biochem Biophys Res Commun 2010;394:439-42
   PubMed Web of Science ®Google Scholar
• Chambliss OL, Jones CM. Cucurbitacins: specific insect attractants in Cucurbitaceae. Science 1966;153:1392-3
   PubMed Web of Science ®Google Scholar
• Miró M. Cucurbitacins and their pharmacological effects. Phytotherapy Research 1995;9:159-68
   Web of Science ®Google Scholar
• Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. Sci World J 2010;10:413-18
   Web of Science ®Google Scholar
• Li Y, Wang R, Ma E, The induction of G2/M cell-cycle arrest and apoptosis by cucurbitacin E is associated with increased phosphorylation of eIF2alpha in leukemia cells. Anticancer Drugs 2010;21:389-400
   PubMed Web of Science ®Google Scholar
• Chen W, Leiter A, Yin D, Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines. Int J Oncol 2010;37:737-43
   PubMed Web of Science ®Google Scholar
• Haritunians T, Gueller S, Zhang L, Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 2008;32:1366-73
   PubMed Web of Science ®Google Scholar
• Chan KT, Meng FY, Li Q, Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 2010;294:118-24
   PubMed Web of Science ®Google Scholar
• Hsu HS, Huang PI, Chang YL, Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 2011;117:2970-85
   PubMed Web of Science ®Google Scholar
• Ouyang D, Zhang Y, Xu L, Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment. Acta Biochim Biophys Sin (Shanghai) 2011;43:487-95
   Google Scholar
• Chen YW, Chen KH, Huang PI, Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma–derived CD44(+)ALDH1(+) cells. Mol Cancer Ther 2010;9:2879-92
   PubMed Web of Science ®Google Scholar
• Lui VW, Yau DM, Wong EY, Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 2009;30:2085-94
   PubMed Web of Science ®Google Scholar
• Rivat C, Rodrigues S, Bruyneel E, Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) – and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 2005;65:195-202
   PubMed Web of Science ®Google Scholar
• Tang JZ, Kong XJ, Banerjee A, STAT3alpha is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone. Endocrinology 2010;151:4133-45
   PubMed Web of Science ®Google Scholar
• Shohat B, Gitter S, Levie B, The combined effect of cucurbitacins and X-ray treatment on transplanted tumors in mice. Cancer Res 1965;25:1828-35
   PubMed Web of Science ®Google Scholar
• Thoennissen NH, Iwanski GB, Doan NB, Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009;69:5876-84
   PubMed Web of Science ®Google Scholar
• Iwanski GB, Lee DH, En-Gal S, Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 2010;160:998-1007
   PubMed Web of Science ®Google Scholar
• Hsu HS, Huang PI, Chang YL, Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 2011;117(13):2970-85
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang M, Zhang H, Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol 2008;587:78-84
   PubMed Web of Science ®Google Scholar
• Maloney KN, Fujita M, Eggert US, Actin-aggregating cucurbitacins from Physocarpus capitatus. J Nat Prod 2008;71:1927-9
   PubMed Web of Science ®Google Scholar
• Momma K, Masuzawa Y, Nakai N, Direct interaction of Cucurbitacin E isolated from Alsomitra macrocarpa to actin filament. Cytotechnology 2008;56:33-9
   PubMed Web of Science ®Google Scholar
• Yin D, Wakimoto N, Xing H, Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 2008;123:1364-75
   PubMed Web of Science ®Google Scholar
• Knecht DA, LaFleur RA, Kahsai AW, Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics. PLoS One 2010;5:e14039
   PubMedGoogle Scholar
• Boykin C, Zhang G, Chen YH, Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation. Br J Cancer 2011;104:781-9
   PubMed Web of Science ®Google Scholar
• Blaskovich MA, Sun J, Cantor A, Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63:1270-9
   PubMed Web of Science ®Google Scholar
• Sun J, Blaskovich MA, Jove R, Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005;24:3236-45
   PubMed Web of Science ®Google Scholar
• Shi X, Franko B, Frantz C, JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulatesnucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol 2006;135:26-32
   PubMed Web of Science ®Google Scholar
• Ishdorj G, Johnston JB, Gibson SB. Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther 2010;9:3302-14
   Google Scholar
• Zhang M, Sun C, Shan X, Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling. Pancreas 2010;39:923-9
   PubMed Web of Science ®Google Scholar
• Jayaprakasam B, Seeram NP, Nair MG. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 2003;189:11-16
   PubMed Web of Science ®Google Scholar
• Siqueira JM Jr, Peters RR, Gazola AC, Anti-inflammatory effects of a triterpenoid isolated from Wilbrandia ebracteata Cogn. Life Sci 2007;80:1382-7
   PubMed Web of Science ®Google Scholar
• Abdelwahab SI, Hassan LE, Sirat HM, Anti-inflammatory activities of cucurbitacin E isolated from Citrullus lanatus var. citroides: role of reactive nitrogen species and cyclooxygenase enzyme inhibition. Fitoterapia 2011;82:1190-7
   PubMed Web of Science ®Google Scholar
• Oh H, Mun YJ, Im SJ, Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med 2002;68:832-3
   PubMed Web of Science ®Google Scholar
• The State Pharmacopoeia Commission of P.R.China. Pharmacopoeia of the People's Republic of China, 2005
   Google Scholar
• Lee S, Kho Y, Min B, Cytotoxic triterpenoides from Alismatis Rhizoma. Arch Pharm Res 2001;24:524-6
   PubMed Web of Science ®Google Scholar
• Law BY, Wang M, Ma DL, Alisol B, a novel inhibitor of the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis. Mol Cancer Ther 2010;9:718-30
   PubMed Web of Science ®Google Scholar
• Chou CC, Pan SL, Teng CM, Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells. Eur J Pharm Sci 2003;19:403-12
   PubMed Web of Science ®Google Scholar
• Huang YT, Huang DM, Chueh SC, Alisol B acetate, a triterpene from Alismatis rhizoma, induces Bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells. Cancer Lett 2006;231:270-8
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang JX, Shen XL, Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem Pharmacol 2004;68:843-55
   PubMed Web of Science ®Google Scholar
• Prieto JM, Recio MC, Giner RM, Influence of traditional Chinese anti-inflammatory medicinal plants on leukocyte and platelet functions. J Pharm Pharmacol 2003;55:1275-82
   PubMed Web of Science ®Google Scholar
• Giner EM, Manez S, Recio MC, In vivo studies on the anti-inflammatory activity of pachymic and dehydrotumulosic acids. Planta Med 2000;66:221-7
   PubMed Web of Science ®Google Scholar
• Ling H, Zhang Y, Ng KY, Pachymic acid impairs breast cancer cell invasion by suppressing nuclear factor-kappaB-dependent matrix metalloproteinase-9 expression. Breast Cancer Res Treat 2011;126:609-20
   PubMed Web of Science ®Google Scholar
• Ling H, Jia X, Zhang Y, Pachymic acid inhibits cell growth and modulates arachidonic acid metabolism in nonsmall cell lung cancer A549 cells. Mol Carcinog 2010;49:271-82
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhang Y, Gapter LA, Cytotoxic and anti-oxidant activities of lanostane-type triterpenes isolated from Poria cocos. Chem Pharm Bull (Tokyo) 2008;56:1459-62
   PubMed Web of Science ®Google Scholar
• Gapter L, Wang Z, Glinski J, Induction of apoptosis in prostate cancer cells by pachymic acid from Poria cocos. Biochem Biophys Res Commun 2005;332:1153-61
   PubMed Web of Science ®Google Scholar
• Li G, Xu ML, Lee CS, Cytotoxicity and DNA topoisomerases inhibitory activity of constituents from the sclerotium of Poria cocos. Arch Pharm Res 2004;27:829-33
   PubMed Web of Science ®Google Scholar
• Tapiero H, Townsend DM, Tew KD. The role of carotenoids in the prevention of human pathologies. Biomed Pharmacother 2004;58:100-10
   PubMed Web of Science ®Google Scholar
• Tanaka T, Shnimizu M, Moriwaki H. Cancer chemoprevention by carotenoids. Molecules 2012;17:3202-42
   PubMed Web of Science ®Google Scholar
• Vaishampayan U, Hussain M, Banerjee M, Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2007;59:1-7
   PubMed Web of Science ®Google Scholar
• Kucuk O, Sarkar FH, Sakr W, Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2001;10:861-8
   PubMed Web of Science ®Google Scholar
• Canene-Adams K, Lindshield BL, Wang S, Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res 2007;67:836-43
   PubMed Web of Science ®Google Scholar
• Kelkel M, Schumacher M, Dicato M, Antioxidant and anti-proliferative properties of lycopene. Free Radic Res 2011;45:925-40
   PubMed Web of Science ®Google Scholar
• Elgass S, Cooper A, Chopra M. Lycopene inhibits angiogenesis in human umbilical vein endothelial cells and rat aortic rings. Br J Nutr 2012;108:431-9
   PubMed Web of Science ®Google Scholar
• Huang CS, Chuang CH, Lo TF, Anti-angiogenic effects of lycopene through immunomodualtion of cytokine secretion in human peripheral blood mononuclear cells. J Nutr Biochem 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Chen ML, Lin YH, Yang CM, Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways. Mol Nutr Food Res 2012;56:889-99
   PubMed Web of Science ®Google Scholar
• Uppala PT, Dissmore T, Lau BH, Selective Inhibition of Cell Proliferation by Lycopene in MCF-7 Breast Cancer Cells In vitro: a Proteomic Analysis. Phytother Res 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Cui Y, Lu Z, Bai L, beta-Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor gamma expression and reactive oxygen species production in MCF-7 cancer cells. Eur J Cancer 2007;43:2590-601
   PubMed Web of Science ®Google Scholar
• Kim Y, Seo JH, Kim H. beta-Carotene and lutein inhibit hydrogen peroxide-induced activation of NF-kappaB and IL-8 expression in gastric epithelial AGS cells. J Nutr Sci Vitaminol (Tokyo) 2011;57:216-23
   PubMed Web of Science ®Google Scholar
• Eid SY, El-Readi MZ, Wink M. Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine 2012;19:977-87
   PubMed Web of Science ®Google Scholar
• Gyemant N, Tanaka M, Molnar P, Reversal of multidrug resistance of cancer cells in vitro: modification of drug resistance by selected carotenoids. Anticancer Res 2006;26:367-74
   PubMed Web of Science ®Google Scholar
• Lee JH, Koo TH, Yoon H, Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006;72:1311-21
   PubMed Web of Science ®Google Scholar
• Yang H, Chen D, Cui QC, Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006;66:4758-65
   PubMed Web of Science ®Google Scholar
• Nagase M, Oto J, Sugiyama S, Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 2003;67:1883-7
   PubMed Web of Science ®Google Scholar
• Hieronymus H, Lamb J, Ross KN, Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006;10:321-30
   PubMed Web of Science ®Google Scholar
• Zhang T, Hamza A, Cao X, A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008;7:162-70
   PubMed Web of Science ®Google Scholar
• Trott A, West JD, Klaic L, Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell 2008;19:1104-12
   PubMed Web of Science ®Google Scholar
• Peng B, Xu L, Cao F, HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer 2010;9:79
   PubMed Web of Science ®Google Scholar
• Zhu H, Liu XW, Cai TY, Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J Pharmacol Exp Ther 2010;334:489-99
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhou Y, Fan Y, Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008;264:101-6
   PubMed Web of Science ®Google Scholar
• Chen G, Wang K, Yang BY, Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol 2012;40:139-47
   PubMed Web of Science ®Google Scholar